Denosumab treatment for glucocorticoid-induced osteoporosis.

IRB
CHLA-19-00127
A phase 3 randomized, double-blind, placebo-controlled, Parallel-group Study to evaluate the safety and efficacy of Denosumab / Prolia in Pediatric Subjects with Glucocorticoid-Induced Osteoporosis

This study will evaluate the effect of Denosumab on lumbar spine mineral density (BMD), as assessed by dual-energy X-Ray absorptiometry (DEXA) at 12 months in children 5 to 17 years of age with GIOP.

Study Details
Clinical Trials Government Identifier
NCT03164928
Keywords
denosumab osteoporosis, glucocorticoid-induced osteoporosis, BMD, spine mineral density
Study Type
Drug Treatment
Eligibility
5 years to 17 years with Glucocorticoid-Induced Osteoporosis
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Sharon Tang
Contact Email
shatang@chla.usc.edu